8-K: Trevi Therapeutics Appoints New Chief Development Officer and Announces Departure of Chief Medical Officer

Trevi Therapeutics has appointed James Cassella as Chief Development Officer, while David Clark has stepped down as Chief Medical Officer.

Summary

• Trevi Therapeutics announced the appointment of James Cassella as Chief Development Officer, effective September 30, 2024.
• Dr. Cassella previously served on Trevi's Board of Directors and has extensive experience in CNS drug development.
• David Clark stepped down as Chief Medical Officer, effective September 27, 2024, to care for a family member.
• Dr. Clark will continue to provide consulting services to Trevi at a rate of $400 per hour.
• Trevi is focused on developing Haduvio for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
• Haduvio is a dual -opioid receptor agonist and -opioid receptor antagonist with potential for a synergistic antitussive effect.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced CDO is a positive development, but the departure of the CMO is a slight negative. The company is progressing with its clinical programs, which is encouraging.

Positives

• The appointment of Dr. Cassella brings significant experience in CNS drug development and regulatory approvals to Trevi.
• Dr. Cassella's prior experience includes leading the development of a successful FDA approved drug.
• Dr. Cassella's existing knowledge of Haduvio from his time on the board should allow for a smooth transition.
• The company has secured consulting services from the outgoing CMO, ensuring continuity of expertise.

Negatives

• The departure of the Chief Medical Officer, Dr. Clark, creates a gap in the executive team.
• The need for Dr. Clark to step down to care for a family member suggests a personal issue that may have impacted the company.

Risks

• The success of Haduvio is subject to the risks and uncertainties of clinical trials.
• Regulatory approvals for Haduvio are not guaranteed.
• The company's future plans and expectations are subject to risks and uncertainties.
• There are no approved therapies for the treatment of chronic cough in IPF and RCC, which highlights the risk of failure.

Future Outlook

Trevi is planning for the pivotal development program in IPF, the advancement in refractory chronic cough, and preparing for a regulatory submission of Haduvio.

Management Comments

• Jennifer Good, President and CEO of Trevi Therapeutics, stated she is delighted to welcome Jim to the executive management team.
• Dr. Cassella said he is excited to join the team at Trevi in a direct leadership role.
• Jennifer Good thanked David for his contributions at Trevi and wished him and his family the best.

Industry Context

The appointment of a new CDO with CNS experience is relevant given Trevi's focus on Haduvio, which has both central and peripheral mechanisms of action. The departure of the CMO is not unusual in the biotech industry, but the company has mitigated the impact by retaining him as a consultant.

Comparison to Industry Standards

• The appointment of a Chief Development Officer with a strong track record in CNS drug development is a positive move for a company like Trevi, which is focused on developing a drug with CNS activity.
• Dr. Cassella's experience at Concert Pharmaceuticals, where he led the development of Leqselvi, a JAK inhibitor, is comparable to the challenges Trevi faces in bringing Haduvio to market.
• The consulting arrangement with the outgoing CMO is a common practice in the biotech industry to ensure continuity of expertise during transitions.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CDO positively.
• Employees may experience changes in leadership and reporting structures.
• The departure of the CMO may cause some uncertainty among stakeholders.

Next Steps

• Trevi will continue to advance the development of Haduvio.
• The company will prepare for a regulatory submission of Haduvio.
• Dr. Cassella will play an integral role in progressing Haduvio.

Key Dates

Keywords

Trevi Therapeutics, Haduvio, Chief Development Officer, Chief Medical Officer, James Cassella, David Clark, Chronic Cough, Idiopathic Pulmonary Fibrosis, Refractory Chronic Cough, CNS Drug Development, Regulatory Approval